Search results for Tanezumab

Tanezumab Biosimilar – Anti-IGHE mAb – Research Grade, ProteoGenix, PX-TA1164

Description of Tanezumab Biosimilar - Anti-IGHE mAb - Research Grade The Structure of Tanezumab Biosimilar – Anti-IGHE mAb Tanezumab Biosimilar, also known as Anti-IGHE mAb, is a monoclonal antibody (mAb) designed to target and neutralize the activity of Immunoglobulin E (IgE). It is a biosimilar version of the original Tanezumab drug, which was developed by Pfizer and is currently in clinical trials for the treatment of chronic pain. The structure of Tanezumab Biosimilar is similar to that of the original Tanezumab drug, with a few modifications to ensure its efficacy and safety as a biosimilar. It is composed of two heavy chains and two light chains, linked together by disulfide bonds. The heavy chains are made up of around 450 amino acids, while the light chains consist of around 220 amino acids. The variable regions of Tanezumab Biosimilar, which are responsible for binding to IgE, are located at the tips of the heavy and light chains. These regions are highly specific and complementary to the IgE molecule, allowing Tanezumab Biosimilar to bind to and neutralize IgE with high affinity. The Activity of Tanezumab Biosimilar The main activity of Tanezumab Biosimilar is its ability to bind to IgE and prevent it from binding to its receptors on immune cells. IgE is an important mediator of allergic reactions and inflammation, and by blocking its activity, Tanezumab Biosimilar can help alleviate symptoms associated with these conditions. In addition to its anti-IgE activity, Tanezumab Biosimilar also has anti-inflammatory effects. It has been shown to inhibit the release of inflammatory mediators from immune cells, which can contribute to the development of chronic pain. This dual mechanism of action makes Tanezumab Biosimilar a promising therapeutic agent for the treatment of chronic pain and other inflammatory conditions. The Application of Tanezumab Biosimilar Tanezumab Biosimilar is currently being studied as a potential treatment for chronic pain, specifically in patients with osteoarthritis, chronic low back pain, and cancer pain. These conditions are often associated with inflammation and increased levels of IgE, making Tanezumab Biosimilar a suitable therapeutic target. In preclinical studies, Tanezumab Biosimilar has shown promising results in reducing pain and improving physical function in animal models of chronic pain. It has also been well-tolerated and has not shown any significant side effects. These findings have led to the initiation of clinical trials to evaluate the safety and efficacy of Tanezumab Biosimilar in humans. As a biosimilar, Tanezumab Biosimilar offers a more affordable alternative to the original Tanezumab drug, making it accessible to a larger population of patients. It also has the potential to improve patient outcomes and quality of life, as chronic pain can significantly impact daily activities and overall well-being. Conclusion Tanezumab Biosimilar, also known as Anti-IGHE mAb, is a monoclonal antibody designed to neutralize the activity of IgE. Its structure is similar to the original Tanezumab drug, with modifications to ensure its efficacy and safety as a biosimilar. Tanezumab Biosimilar has anti-IgE and anti-inflammatory activity, making it a promising therapeutic target for chronic pain and other inflammatory conditions. It is currently being studied in clinical trials and has the potential to improve patient outcomes and quality of life as a more affordable treatment option.

Tanezumab, Kyinno, KB-1028

Tanezumab, Abbexa, abx831119

Tanezumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGHE, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.

Tanezumab ELISA Kit, ProteoGenix, KPTX126

Description of Tanezumab ELISA Kit Introduction to Tanezumab ELISA Kit Tanezumab is a humanized monoclonal antibody that targets nerve growth factor (NGF), a protein involved in the growth, maintenance, and repair of nerve cells. It is currently being developed as a potential therapy for chronic pain conditions, such as osteoarthritis and chronic low back pain. The Tanezumab ELISA Kit is a highly sensitive and specific tool used to measure the levels of Tanezumab in biological samples. In this article, we will discuss the structure, activity, and application of the Tanezumab ELISA Kit. Structure of Tanezumab ELISA Kit The Tanezumab ELISA Kit is composed of several components, including microtiter plates, Tanezumab-specific antibodies, and detection reagents. The microtiter plates are coated with a specific antibody that captures Tanezumab in the sample. The Tanezumab-specific antibodies are labeled with an enzyme, such as horseradish peroxidase (HRP), which produces a color change when exposed to the detection reagents. This color change can then be measured using a spectrophotometer, which determines the amount of Tanezumab in the sample. Activity of Tanezumab ELISA Kit The Tanezumab ELISA Kit works on the principle of antigen-antibody binding. When a sample containing Tanezumab is added to the microtiter plate, the Tanezumab-specific antibodies bind to the Tanezumab present in the sample. After washing away any unbound components, the detection reagents are added, which react with the enzyme-labeled antibodies. This reaction produces a color change that is directly proportional to the amount of Tanezumab present in the sample. The intensity of the color is measured using a spectrophotometer, and the concentration of Tanezumab in the sample is calculated using a standard curve. Application of Tanezumab ELISA Kit The Tanezumab ELISA Kit has multiple applications in the field of drug development and clinical research. It is primarily used to measure the levels of Tanezumab in biological samples, such as serum, plasma, and tissue homogenates. This allows researchers to monitor the pharmacokinetics of Tanezumab and evaluate its efficacy in clinical trials. The Tanezumab ELISA Kit can also be used to screen potential drug candidates that target NGF, as it can accurately measure the levels of Tanezumab in the presence of other NGF-targeting compounds. The Tanezumab ELISA Kit is also a valuable tool in preclinical research, as it can be used to measure the levels of Tanezumab in animal models. This allows researchers to determine the appropriate dosage and treatment regimen for Tanezumab before moving on to human trials. Additionally, the Tanezumab ELISA Kit can be used to study the distribution and elimination of Tanezumab in different tissues and organs, providing valuable insights into its mechanism of action. Conclusion In conclusion, the Tanezumab ELISA Kit is a highly sensitive and specific tool for measuring the levels of Tanezumab in biological samples. Its structure, activity, and application make it an essential component in the development and evaluation of Tanezumab as a potential therapy for chronic pain conditions. As research on Tanezumab continues, the Tanezumab ELISA Kit will play a crucial role in advancing our understanding of this promising therapeutic target.

Tanezumab ELISA Kit, Abbexa, abx395015

Tanezumab ELISA Kit is a quantitative ELISA kit for detection of Tanezumab.Tanezumab (RN624) is a recombinant humanized anti- nerve growth factor (NGF) monoclonal antibody (IgG2 type) that works by inhibiting the binding of NGF to its receptors. It was developed by Pfizer as a treatment for pain.

Tanezumab Biosimilar - Research Grade, ichor.bio, ICH5102

Detects human NGF

Research Grade Tanezumab (HF909016), abinScience, HF909016